HUTCHMED (China) Investor Relations Material
Latest events
H2 2024
HUTCHMED (China)
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from HUTCHMED (China) Limited
Access all reports
HUTCHMED Limited is a global biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases. The company integrates innovative science and clinical expertise to develop a robust pipeline of therapies, leveraging its research and development capabilities in China and internationally. HUTCHMED markets its products in various regions and collaborates with global pharmaceutical partners for distribution and development. The company is headquartered in Hong Kong, China, and its shares are listed on the NASDAQ and the London Stock Exchange (LSE).
Key slides for HUTCHMED (China) Limited
H1 2024
HUTCHMED (China) Limited
R&D Update
HUTCHMED (China) Limited
Latest articles
)
The Rise and Fall of Wirecard
A look inside the Wirecard scandal, which took the company from the prestigious DAX 30 to insolvency through the largest accounting fraud in European history.
16 May 2025
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
Ticker symbol
HCM
Country
🇬🇧 United Kingdom